Letters the National Heart, Lung, and Blood Institute and the Greenwall Foundation. Dr and the results were nearly identical; compared with IABP, use Mortazavi reported receipt of grants and nonfinancial support from the of intravascular microaxial LVAD was associated with a sig- American College of Cardiology and the FDA. Dr Desai reported receipt of nificantly higher risk of in-hospital death (44.9% vs 33.0%; ab- grants and personal fees from Amgen, Boehringer Ingelheim, and Cytokinetics solute risk difference, 11.8 [95% CI, 8.6-15.1] percentage points; and receipt of personal fees from The Medicines Company, Novartis, Relypsa, and scPharmaceuticals. P < .001) and in-hospital major bleeding (31.5% vs 15.1%; ab- 1. Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular solute risk difference, 16.4 [95% CI, 13.6-19.2] percentage microaxial left ventricular assist device vs intra-aortic balloon pump with points; P < .001). in-hospital mortality and major bleeding among patients with acute myocardial Ravn et al also refer to their observational study finding a infarction complicated by cardiogenic shock. JAMA. 2020;323(8):734-745. relationship between early use of an intravascular microaxial doi:10.1001/jama.2020.0254 LVAD and improved outcomes. While there have been con- 2. Helgestad OKL, Josiassen J, Hassager C, et al.
JAMA – American Medical Association
Published: Jul 21, 2020